Global, regional, and national burden of cancers attributable to occupational risks from 1990 to 2019
Journal of Occupational Health · 2024
DOI: 10.1093/joccuh/uiae040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Occupational Health, 2024. Verfasst von Shiliang Ling und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, …. Hauptthemen laut MEDLINE: Global Burden of Disease, Neoplasms, Occupational Exposure, Cost of Illness. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINGBO Medical & Health Leading Academic Discipline Project, and National Chinese Medicine Specialty, Ningbo Nature Foundation.
Abstract (Originalsprache)
Background
Based on data from the Global Burden of Disease study, the burden of cancer attributable to occupational risks between 1990 and 2019 was explored.
Methods
The estimated burden in different regions was compared in terms of the age-standardized death rates (ASDRs), age-standardized disability-adjusted life years (DALYs) rates, and corresponding estimated annual percentage changes (EAPCs). The comparative risk assessment framework was used to estimate the risk of death and DALYs attributable to occupational risk factors.
Results
Globally from 1990 to 2019, ASDRs decreased (EAPC = −0.69; 95% CI: −0.76 to −0.61), and age-standardized DALY rates decreased (EAPC = −0.99; 95% CI: −1.05 to −0.94). In terms of the global age distribution of cancer attributable to occupational risk factors, the death rate and DALY rates increased with age. In addition, from 1990 to 2019, the number of deaths, DALYs, ASDRs, and age-standardized DALY rates in men were higher than those in women, and the cancer burden grew fastest in Georgia (EAPC = 5.04), Croatia (EAPC = 4.01), and Honduras (EAPC = 3.54). Moreover, as the sociodemographic index (SDI) value of a country or region increased, its burden of cancer attributable to occupational risk factors rapidly increased.
Conclusions
The global cancer burden attributable to occupational risk factors declined from 1990 to 2019, was higher in men than in women, and was concentrated in middle-aged and older adults. The baseline cancer burdens of regions or countries increased as their SDI values increased and were especially high in high-SDI regions or countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, Zhejiang, China.
- Department of Spleen and Stomach, Shanghai Pudong New Area Traditional Chinese Medicine Hospital, Shanghai, China.
- Department of Anesthesiology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, Zhejiang, China.
ORCID-Profile: Yanfeng Wu
Förderung
- NINGBO Medical & Health Leading Academic Discipline Project, and National Chinese Medicine Specialty
- Ningbo Nature Foundation
Zitieren
APA
Ling, S., Zhou, L., Wu, Y., Zhang, X., Han, W., Cui, L., & Luan, Z. (2024). Global, regional, and national burden of cancers attributable to occupational risks from 1990 to 2019. Journal of Occupational Health. https://doi.org/10.1093/joccuh/uiae040
Vancouver
Ling S, Zhou L, Wu Y, Zhang X, Han W, Cui L, et al. Global, regional, and national burden of cancers attributable to occupational risks from 1990 to 2019. Journal of Occupational Health. 2024. doi:10.1093/joccuh/uiae040
BibTeX
@article{Ling2024,
author = {Ling, Shiliang and Zhou, Lihong and Wu, Yanfeng and Zhang, Xiaoling and Han, Wulong and Cui, Lihua and Luan, Zhiyu},
title = {Global, regional, and national burden of cancers attributable to occupational risks from 1990 to 2019},
journal = {Journal of Occupational Health},
year = {2024},
doi = {10.1093/joccuh/uiae040}
}
EUVIMED